This appeal challenges the district court’s conclusion that the policy issued by Third-Party Defendant New York Marine & General Insurance Company (“NY Marine”) to Phoenix Laboratories, Inc. (“Phoenix”) provided no coverage to Third-Party Plaintiff-Appellant CCA Industries, Inc. (“CCA”) and that NY Marine had no obligation to defend or indemnify CCA. For reasons stated below, we vacate and remand for further proceedings.
I.
Plaintiff Robert Weaver (“Weaver”) brought this lawsuit to recover for injuries he allegedly sustained from ingesting Per-mathene, a product marketed and sold by CCA. In 1995, Weaver began taking Per-mathene, an over-the-counter diet drug/appetite suppressant which contains phenylpropanolamine (“PPA”). Eleven days after he began taking Permathene, Weaver suffered a hemorrhagic stroke. Weaver contends that the PPA in Per-mathene caused his stroke.
Weaver filed this products liability suit against CCA, as manufacturer and seller of Permathene. Weaver contends that Permathene was unreasonably dangerous due to defective manufacture and design, Permathene failed to conform to CCA’s express warranty, CCA failed to provide an adequate warning regarding the risks associated with Permathene, and CCA negligently failed to adequately and properly test Permathene.
Although GCA sells and markets Per-mathene, Phoenix manufactures the product. Using a formula provided by CCA,
Weaver has not asserted any claim against Phoenix directly. CCA made demands on Phoenix’s insurer, NY Marine, for defense and indemnification of any damages it might have to pay Weaver. NY Marine declined coverage and the request for defense in July 2002, and again in May 2006.
It is undisputed that NY Marine had in effect a Claims-Made Products/Completed Operations Liability Insurance Policy (the “Policy”) affording liability coverage to Phoenix and other insureds. The Policy provides coverage to its insureds for “those sums that the insured becomes legally obligated to pay as damages because of ‘bodily injury’ or ‘property damage’ included within the ‘products-completed operations hazard’ to which the insurance applies.”
In June 2006, CCA filed a third-party complaint against Phoenix and against NY Marine for defense and indemnification. CCA asserts that Phoenix obtained a claims-made liability policy from NY Marine and that under its vendor’s endorsement, the Policy afforded liability coverage to CCA for liability arising out of its sale of the product manufactured by Phoenix.
CCA was not a named insured under the Policy and does not claim coverage on this basis. CCA claims coverage under the Policy’s vendor’s endorsement (“Endorsement # 5”), which provides in full:
ENDORSEMENT # 5
ADDITIONAL ASSURED — VENDORS
(BROAD FORM — BLANKET BASIS)
In consideration of the premium charged, it is hereby agreed that the definition of insured is amended to include any person or organization designated as a vendor but only with respect to the distribution or sale in the regular course of the vendor’s business of the Named Insured’s products subject to the following additional provisions:
1. The insurance with respect to the vendor does not apply to:
(a) any express warranty unauthorized by the named insured;
(b) bodily injury or property damage arising out of
(i) any physical or chemical change in the form of the product made intentionally by the vendor,
(ii) repacking, unless unpacked solely for the purpose of inspection, demonstration, testing or the substitution of parts under instruction from the manufacturer and then repacked in the original container,
(iii) demonstration, installation, servicing or repair operations, except such operations performed at the vendor’s premises in connection with the sale of the product, or
(iv) products which after distribution or sale by the named insured have been labeled or relabeled or used as a container, part or ingredient of any other thing or substance by or for the vendor.
2. The insurance does not apply to any person or organization, as insured, from whom the named insured has acquired such products or any ingredient, part or container, entering into, accompanying or containing such products.
ALL OTHER TERMS AND CONDITIONS REMAIN UNCHANGED.
NY Marine filed a motion for summary judgment, which the district court granted.
II.
A.
We review the district court’s grant of summary judgment
de novo. Facility Ins. Corp. v. Employers Ins. of Wausau,
B.
The parties agree that Louisiana law governs interpretation of the Policy. The Louisiana Supreme Court recently announced a number of helpful rules to guide us in interpreting insurance policies.
See generally Cadwallader v. Allstate Ins. Co.,
CCA argues that it is entitled to both defense and indemnity. With respect to the duty to defend, the Louisiana Supreme Court has set out the appropriate standard as follows:
Generally the insurer’s obligation to defend suits against its insured is broader than its liability for damage claims. The insurer’s duty to defend suits brought against its insured is determined by the allegations of the injured plaintiffs petition, with the insurer being obligated to furnish a defense unless the petition unambiguously excludes coverage. Thus, if, assuming all the allegations of the petition to be true, there would be both (1) coverage under the policy and (2) liability to the plaintiff, the insurer must defend the insured regardless of the outcome of the suit. Additionally, the allegations of the petition are liberally interpreted in determining whether they set forth grounds which bring the claim within the scope of the insurer’s duty to defend the suit brought against its insured.
Yount v. Maisano, 621
So.2d 148, 153 (La.1993) (citing
Am. Home Assurance Co. v.
C.
We now turn to the first issue presented in this appeal: whether CCA qualifies as an additional insured under the vendor’s endorsement in the Policy NY Marine issued to Phoenix. 1 The critical language in Endorsement # 5 provides: “it is hereby agreed that the definition of insured is amended to include any person or organization designated as a vendor but only with respect to the distribution or sale in the regular course of the vendor’s business in [Phoenix’s] products subject to the following additional provisions .... ”
The district court correctly found that CCA qualifies as a vendor. But this does not completely answer our question. Under Louisiana law, vendor’s endorsements “have been interpreted as providing coverage where the vendor is found strictly liable for selling a defective product and excluding coverage where the vendor is found to be independently negligent.”
McGill v. Cochran-Sysco Foods,
It is true that Weaver’s petition asserts that CCA was independently negligent in a number of respects. However, Weaver’s complaint also asserts a strict liability claim under the Louisiana Product Liability Act (“LPLA”) based on the allegation that the product was unreasonably dangerous in construction or composition. 2 Louisiana courts have made it clear that liability under the LPLA may be based on strict liability. 3
First, NY Marine argues that exclusion l(b)(iv) excludes coverage for this claim because CCA “labeled” the product after Phoenix sold the product in bulk to CCA. 5 It is undisputed that the product arrived in bulk from Phoenix and was packaged, labeled, and marketed by CCA. CCA agues, however, that this is not enough to trigger the exclusion because no nexus has been shown between CCA’s labeling or other alteration of the product and Weaver’s injury.
Very few cases have considered this precise issue of whether an insurer must show a nexus between the labeling or alteration of the product and the injury. We find the two federal court decisions on the issue most persuasive. In
Mattocks v. Daylin Inc., 452
F.Supp. 512 (W.D.Pa.1978),
aff'd.,
In
Sears, Roebuck and Co. v. Reliance,
Couch on Insurance states that if the exclusion is written to apply once the insured’s product has been relabeled, injury must arise out of the relabeling or out of the use of the insured’s product as a part of another product in order for coverage to be excluded. 7 Although no Louisiana court has considered this particular exclusion in this context, most courts which have considered this question have required this nexus. See supra. Thus, our best Erie guess is that Louisiana would adopt the majority position and require the nexus between the alteration and the injury.
In his complaint, Weaver asserted a number of product liability theories in support of recovery. He alleged that the product was unreasonably dangerous due to defective manufacture and design, that the product failed to conform to CCA’s express warranty, that CCA failed to adequately and properly test the product, and that CCA failed to provide adequate warning. Arguably, Weaver’s claim predicated on a failure to warn theory has a nexus to CCA’s relabeling of the product. But, as in
Mattocks,
Weaver has a number of other recovery theories that have no nexus to
We turn, finally, to exclusion 2. 8 NY Marine argued, and the district court agreed, that the formula provided by CCA to Phoenix was an “ingredient” for the purposes of this exclusion. We disagree. This interpretation of ingredient is inconsistent with the common sense meaning of that word. There is a logical, common sense distinction between the formula, a list of ingredients, and the ingredients themselves. A simple desktop dictionary defines “formula” as “a prescription of ingredients in fixed proportion.” Webster’s II New Riverside University Dictionary 499 (1984). “Ingredient is defined as ‘[a] constituent element of a mixture or compound.’ ” Id. at 628. In short, the formula or recipe for a product is different from the ingredients used to create the product. Noone would say that a recipe for lemon pie is one of the ingredients the baker uses to make the pie. We thus conclude that the district court also erred in finding exclusion 2 applicable. 9
III.
The district court erred in holding that exclusion l(b)(iv) and exclusion 2 exclude coverage for Weaver’s LPLA claim. Exclusion l(b)(iv) is inapplicable because there existed no nexus between the harm alleged in some of Weaver’s claims and the alteration and relabeling of the product. Exclusion 2 is inapplicable because the formula for a product is not an “ingredient” for purposes of making that product. For these reasons, we vacate the district court’s judgment and remand this case to the district court for further proceedings not inconsistent with this opinion.
VACATE and REMAND.
Notes
. CCA also asserts that certain Certificates of Liability Insurance ("COLI”) naming CCA as the certificate holder and an additional insured under the NY Marine policy give rise to coverage, but even if we were to assume, as the plaintiff asserts, that the COLI were issued by an agent of NY Marine, the COLI cannot affect the terms of the underlying insurance policy. At the top of the certificate appears a statement that the COLI is informational only and does not confer rights to the holder nor does it amend, extend, or alter the coverage outlined in the policies. Thus we must look to the Policy, not the COLI, to determine coverage.
. La. R.S. § 9:2800.55 (“A product is unreasonably dangerous in construction or composition if, at the time the product left its manufacturer’s control, the product deviated in a material way from the manufacturer's specifications or performance standards for the product or from otherwise identical products manufactured by the same manufacturer.”). The LPLA is applicable to pharmaceutical products.
See, e.g., Stahl v. Novartis Pharm. Corp.,
.See, e.g., Lawson v. Mitsubishi Motor Sales of Am., Inc.,
. La. R.S. § 9:2800.53 provides, in relevant part:
(1) “Manufacturer” means a person or entity who is in the business of manufacturing a product for placement into trade or commerce. "Manufacturing a product” means producing, making, fabricating, constructing, designing, remanufacturing, reconditioning or refurbishing a product. "Manufacturer” also means:
(a) A person or entity who labels a product as his own or who otherwise holds himself out to be the manufacturer of the product.
(b) A seller of a product who exercises control over or influences a characteristic of the design, construction or quality of the product that causes damage ....
La. R.S. § 9:2800.53.
. Exclusion l(b)(iv) reads:
The insurance with respect to the vendor does not apply to ... bodily injury or property damage arising out of ... products which after distribution or sale by the named insured have been labeled or relabeled or used as a container, part or ingredient of any other thing or substance by or for the vendor.
. "Section 1 (b)(i) excludes coverage with respect to any bodily injury 'arising out of any intentional, physical change in form of the product by the vendor.”
Mattocks,
. Couch on Insurance § 130:10 (3d ed. 2007) (Citing
Mattocks,
. Exclusion 2 reads: “The insurance does not apply to any person or organization, as insured, from whom the named insured has acquired such products or any ingredient, part or container, entering into, accompanying or containing such products.”
. We need not address CCA’s motion to supplement the appellate record because the purpose of the supplement was to demonstrate that the formula for a product is not the same as the ingredients used to create the product.
